The combination of decitabine and vorinostat does not appear to be feasible in the treatment of children with B-cell acute lymphoblastic leukaemia (B-ALL), despite encouraging response rates and pharmacodynamics, because of increased incidence of significant infectious toxicities, according to data from the TACL* pilot study.
About two in three men with prostate cancer are at increased cardiovascular (CV) risk, suggests a recent study. A positive association exists between a plan to use androgen deprivation therapy and baseline CV risk factors, but such link is explained by confounding factors.
In patients with localized prostate cancer undergoing external beam radiotherapy, use of the orally administered androgen deprivation therapy relugolix results in rapid and sustained suppression of testosterone to castrate levels, with a tolerable safety profile, according to the results of a phase II trial.
Platinum-based neoadjuvant chemotherapy appears to be beneficial in patients with bulky regional lymph node metastases from penile cancer, with nearly 50 percent responding to treatment and about 16 percent achieving a pathological complete response, results of a systematic review and meta-analysis have shown.
The incidence of infection is similar between head and neck cancer patients who received antimicrobial prophylaxis and those who did not, results of a recent study have shown. In addition, no difference is observed in the incidence of hospitalization, but the length of hospital stay is longer in the prescribed prophylactic group.
Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.
Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.
At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.
“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.
Case presentation: The
patient is a 46-year-old Korean lady who first presented with aggravating
pleuritic chest pain characterised by a stabbing pain in the chest when
inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was
made from computed tomography (CT)-guided needle aspiration biopsy, and the
tumour was found to be epidermal growth factor receptor (EGFR)
mutation-positive (exon 19 deletion). Chest imaging revealed the presence of
left-sided pleural seeding nodules. The patient was treated with afatanib with
partial response as best response. Ten months after starting treatment, the
patient experienced disease progression.